INmune Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.043 million compared to USD 0.098 million a year ago. Net loss was USD 8.56 million compared to USD 7.73 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.43 a year ago.
For the nine months, sales was USD 0.127 million compared to USD 0.277 million a year ago. Net loss was USD 21.6 million compared to USD 21.47 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 1.2 a year ago.